Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBRUNONI, A. R.
dc.contributor.authorLOTUFO, P. A.
dc.contributor.authorSABBAG, C.
dc.contributor.authorGOULART, A. C.
dc.contributor.authorSANTOS, I. S.
dc.contributor.authorBENSENOR, I. M.
dc.date.accessioned2015-10-26T16:25:07Z
dc.date.available2015-10-26T16:25:07Z
dc.date.issued2015
dc.description.abstractBrain-derived neurotrophic factor (BDNF) is associated with neuroplasticity and synaptic strength, and is decreased in conditions associated with chronic stress. Nevertheless, BDNF has not yet been investigated in psoriasis, a chronic inflammatory systemic disease that is exacerbated by stress. Therefore, our aim was to determine BDNF plasma levels in psoriasis patients and healthy controls. Adult patients (n = 94) presenting with psoriasis for at least 1 year were enrolled, and age-and gender-matched with healthy controls (n = 307) from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Participants had neither a previous history of coronary artery disease nor current episode of major depression. BDNF plasma levels were determined using the Promega ELISA kit. A general linear model was used to compare BDNF levels in psoriasis patients and controls, with age, gender, systolic blood pressure, serum fasting glucose, blood lipid levels, triglycerides, smoking status, and body mass index examined. After adjusting for clinical and demographic variables, significantly decreased BNDF plasma levels were observed in psoriasis patients (P = 0.01) (estimated marginal means of 3922 pg/mL; 95% CI = 2660-5135) compared with controls (5788 pg/mL; 95% CI = 5185-6442). Similar BDNF levels were found in both mild and severe cases of psoriasis. Our finding, that BDNF is decreased in psoriasis, supports the concept of a brain-skin connection in psoriasis. Further studies should determine if BDNF is increased after specific psoriasis treatments, and associated with different disease stages.
dc.description.indexMEDLINE
dc.description.sponsorshipBrazilian Ministry of Health (Science and Technology Department)
dc.description.sponsorshipBrazilian Ministry of Science and Technology (Financiadora de Estudos e Projetos and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)) [01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, 01 06 0071.00 RJ]
dc.description.sponsorshipCNPq
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAEPSP) [2012/20911-5]
dc.identifier.citationBRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.48, n.8, p.711-714, 2015
dc.identifier.doi10.1590/1414-431X20154574
dc.identifier.eissn1678-4510
dc.identifier.issn0100-879X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/11536
dc.language.isoeng
dc.publisherASSOC BRAS DIVULG CIENTIFICA
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsopenAccess
dc.rights.holderCopyright ASSOC BRAS DIVULG CIENTIFICA
dc.subjectBrain derived neurotrophic factor
dc.subjectPsoriasis
dc.subjectNeurotrophins
dc.subjectPsychological stress
dc.subjectCase-control study
dc.subject.otherbdnf
dc.subject.otherstress
dc.subject.otherseverity
dc.subject.wosBiology
dc.subject.wosMedicine, Research & Experimental
dc.titleDecreased brain-derived neurotrophic factor plasma levels in psoriasis patients
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus29
hcfmusp.contributor.author-fmusphcANDRE RUSSOWSKY BRUNONI
hcfmusp.contributor.author-fmusphcPAULO ANDRADE LOTUFO
hcfmusp.contributor.author-fmusphcCID YAZIGI SABBAG
hcfmusp.contributor.author-fmusphcALESSANDRA CARVALHO GOULART
hcfmusp.contributor.author-fmusphcITAMAR DE SOUZA SANTOS
hcfmusp.contributor.author-fmusphcISABELA JUDITH MARTINS BENSEñOR
hcfmusp.description.beginpage711
hcfmusp.description.endpage714
hcfmusp.description.issue8
hcfmusp.description.volume48
hcfmusp.origemWOS
hcfmusp.origem.pubmed26200230
hcfmusp.origem.scieloSCIELO:S0100-879X2015000800711
hcfmusp.origem.scopus2-s2.0-84938683922
hcfmusp.origem.wosWOS:000358776500007
hcfmusp.publisher.citySAO PAULO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceAquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
hcfmusp.relation.referenceBath KG, 2013, NEUROSCIENCE, V239, P149, DOI 10.1016/j.neuroscience.2013.01.074
hcfmusp.relation.referenceBrunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309
hcfmusp.relation.referenceBrunoni AR, 2014, BRAZ J MED BIOL RES, V47, P1102, DOI 10.1590/1414-431X20143762
hcfmusp.relation.referenceConsoli SM, 2006, DERMATOLOGY, V212, P128, DOI 10.1159/000090653
hcfmusp.relation.referenceDuman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013
hcfmusp.relation.referenceFuchikami M, 2010, PSYCHIAT INVEST, V7, P251, DOI 10.4306/pi.2010.7.4.251
hcfmusp.relation.referenceNestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
hcfmusp.relation.referenceNunes M. A., 2011, REV HCPA, V31, P487
hcfmusp.relation.referenceOsorio FD, 2009, PERSPECT PSYCHIATR C, V45, P216
hcfmusp.relation.referencePan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5
hcfmusp.relation.referencePaus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002
hcfmusp.relation.referenceQuan C, 2014, MOL BIOL REP, V41, P7015, DOI 10.1007/s11033-014-3589-4
hcfmusp.relation.referenceRaap U, 2006, ALLERGY, V61, P1416, DOI 10.1111/j.1398-9995.2006.01210.x
hcfmusp.relation.referenceRampton DS, 2011, J RHEUMATOL, V38, P43, DOI 10.3899/jrheum.110904
hcfmusp.relation.referenceSaha RN, 2006, J NEUROIMMUNE PHARM, V1, P212, DOI 10.1007/s11481-006-9020-8
hcfmusp.relation.referenceSaraceno R, 2006, BRIT J DERMATOL, V155, P876, DOI 10.1111/j.1365-2133.2006.07518.x
hcfmusp.relation.referenceStaniak HL, 2014, ATHEROSCLEROSIS, V237, P847, DOI 10.1016/j.atherosclerosis.2014.11.004
hcfmusp.relation.referenceTruzzi F, 2011, CELL DEATH DIFFER, V18, P948, DOI 10.1038/cdd.2010.162
hcfmusp.relation.referenceVasiadi M, 2012, BRIT J DERMATOL, V166, P1349, DOI 10.1111/j.1365-2133.2012.10843.x
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7d074e1c-d01c-47ef-a563-4fc4444a8219
relation.isAuthorOfPublicationcb0c8dbb-6df5-4294-8d8e-e96645a3cec1
relation.isAuthorOfPublicatione424494a-256a-4ccf-9d32-61f66721c3cc
relation.isAuthorOfPublicationcd675f04-b4ad-47f1-8d3c-15f6cb73d8cf
relation.isAuthorOfPublicatione566281f-a9d6-4882-b281-5031a0141a11
relation.isAuthorOfPublication6911f59e-7ec9-4ad2-b746-580bf8b3d64d
relation.isAuthorOfPublication.latestForDiscovery7d074e1c-d01c-47ef-a563-4fc4444a8219
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_BRUNONI_Decreased_brainderived_neurotrophic_factor_plasma_levels_in_psoriasis_2015.PDF
Tamanho:
94.39 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/27
Artigos e Materiais de Revistas Científicas - LIM/51
Carregar mais